Livzon Pharmaceutical Group Inc.
000513
Rang in aandelen
#4689
Livzon Pharmaceutical Group Inc., headquartered in Zhuhai, China, and... Livzon Pharmaceutical Group Inc., headquartered in Zhuhai, China, and established in 1985, is a biopharmaceutical enterprise operating across the entire spectrum of pharmaceutical activities, from research and development to manufacturing and commercialization. The company's operations encompass a diverse range of finished drug products, active pharmaceutical ingredients (APIs), and chemical intermediates, primarily serving the Chinese market while also engaging in international exports. Its pharmaceutical portfolio includes treatments such as Ilaprazole enteric coated tablets for duodenal ulcers and reflux esophagitis, Laprazole sodium injection for managing peptic ulcer bleeding, Leuprorelin Acetate Microspheres for injection, and Urofollitropin injection for anovulation and fertility support. Livzon also produces Perospirone Hydrochloride for schizophrenia, Anti-viral Granules targeting upper respiratory tract infections and influenza, and Shenqi Fuzheng Injection, which addresses general weakness, fatigue, spontaneous sweating, and vertigo, and provides supportive care for lung and stomach cancer patients. Beyond therapeutic drugs, Livzon Pharmaceutical Group develops and distributes a variety of diagnostic reagents. These include kits for detecting IgM/IgG antibodies to coronavirus, nucleic acid tests for human immunodeficiency virus type 1, antinuclear antibody test kits, interferon-gamma release assay kits, and rapid tests for mycoplasma pneumoniae IgM antibodies. The company's extensive offerings further extend to biochemical drugs, microbiological preparations, biologics, traditional Chinese medicine formulations, pharmaceutical raw materials, and antibiotics.
Aandeelprijs
$3.90
Marktkapitalisatie
$3.17B
Verandering (1 dag)
-3.49%
Verandering (1 jaar)
-25.88%
Land
CN
Handel Livzon Pharmaceutical Group Inc. (000513)
Categorie
Healthcare
Omzet van Livzon Pharmaceutical Group Inc. (000513)
Omzet in Jun 2026 TTM: $1.61B
Volgens de laatste financiële rapporten van Livzon Pharmaceutical Group Inc. bedraagt de huidige omzet van het bedrijf (TTM) $1.61B. In 2024 behaalde het bedrijf een omzet van $1.62B een daling ten opzichte van de omzet in het jaar 2023, die $1.76B bedroeg. De omzet is het totale bedrag aan inkomsten dat een bedrijf genereert door de verkoop van goederen of diensten. In tegenstelling tot de winst worden er geen kosten afgetrokken.
Omzetgeschiedenis van Livzon Pharmaceutical Group Inc. van 2001 tot 2026
Omzet aan het einde van elk jaar
| Jaar | Omzet | Wijzigen |
|---|---|---|
| 2026 (TTM) | $1.61B | -5.45% |
| 2025 | $1.70B | 5.18% |
| 2024 | $1.62B | -7.84% |
| 2023 | $1.76B | -4.09% |
| 2022 | $1.83B | -3.54% |
| 2021 | $1.90B | 17.86% |
| 2020 | $1.61B | 19.49% |
| 2019 | $1.35B | 4.63% |
| 2018 | $1.29B | -1.76% |
| 2017 | $1.31B | 18.97% |
| 2016 | $1.10B | 8.10% |
| 2015 | $1.02B | 13.90% |
| 2014 | $895.10M | 17.55% |
| 2013 | $761.43M | 20.40% |
| 2012 | $632.40M | 26.05% |
| 2011 | $501.72M | 21.45% |
| 2010 | $413.11M | 8.65% |
| 2009 | $380.22M | 26.03% |
| 2008 | $301.69M | 26.02% |
| 2007 | $239.41M | 17.50% |
| 2006 | $203.75M | 1.14% |
| 2005 | $201.46M | 7.23% |
| 2004 | $187.88M | -14.19% |
| 2003 | $218.94M | 13.17% |
| 2002 | $193.46M | 14.69% |
| 2001 | $168.68M | 0.00% |
Omzet van vergelijkbare bedrijven of concurrenten
| Bedrijf | Omzet | Omzetverschil | Land |
|---|---|---|---|
| $23.54B | 1,362.30% |
DE
|
|
| $23.73B | 1,374.71% |
DE
|
|
| $29.24B | 1,716.72% |
JP
|
|
| $5.85B | 263.40% |
CH
|
|
| $6.34B | 294.06% |
IN
|
